Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

newport pharmaceuticals de costa rica, s.a. - solución oral - 1 g/5ml

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

inovet - l arginina, monoclorhidrato:; inosina base:; excipientes c.s.p.: - l arginina, monoclorhidrato: - 50 mg;; inosina base: - 20 mg.; excipientes c.s.p.: - 100 ml. - desinflamante, cicatrizante y reepitelizante eficaz en lesiones podales. - bovinos; equinos; ovinos;

Argentina - español - SANI (Asociación de Cooperativas Argentinas)

inovet - l arginina, monoclorhidrato:; inosina base:; excipientes c.s.p.: - l arginina, monoclorhidrato: - 25 mg.; inosina base: - 15 mg.; excipientes c.s.p.: - 100 ml. - eleva inespecificamente las defensas orgánicas con el objeto de obtener una rápida desinflamación y aceleración de la cicatrización, epiteliando eficazmente las lesiones oculares. - bovinos; equinos; ovinos;

Unión Europea - español - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - asma - medicamentos para la enfermedad obstructiva de las vías respiratorias enfermedades, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para la dermatitis, excluidos los corticosteroides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - espinosad - comprimido masticable - excipientes: celulosa microcristalina, aroma de carne artificial, hidroxipropilcelulosa (e463), silice coloidal anhidra, croscarmelosa sodica, estearato de magnesio - spinosad - perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - espinosad - comprimido masticable - excipientes: aroma artificial de ternera en polvo (irradiado), celulosa microcristalina, hidroxipropilcelulosa (e463), croscarmelosa sodica, dioxido de silice coloidal, estearato de magnesio - spinosad - gatos, perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - espinosad - comprimido masticable - excipientes: aroma artificial de ternera en polvo (irradiado), celulosa microcristalina, hidroxipropilcelulosa (e463), croscarmelosa sodica, dioxido de silice coloidal, estearato de magnesio - spinosad - gatos, perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - espinosad - comprimido masticable - excipientes: celulosa microcristalina, aroma de carne artificial, silice coloidal anhidra, croscarmelosa sodica, estearato de magnesio, hidroxipropilcelulosa (e463) - spinosad - gatos, perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - espinosad - comprimido masticable - excipientes: celulosa microcristalina, aroma de carne artificial, hidroxipropilcelulosa (e463), silice coloidal anhidra, croscarmelosa sodica, estearato de magnesio - spinosad - gatos, perros